drugset
drugset / Trial / NCT04672512

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants

NCT04672512 ↗

Phase 1 Completed 115 enrolled Corcept Therapeutics
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to evaluate the dose-related safety, tolerability, pharmacokinetics (PK) and pharmacological effects (PD) of CORT125329 after single and multiple ascending oral doses of CORT125329 lipid capsule formulations in healthy participants.

Timeline

Start
2020-10-23
Primary completion
2022-01-17
Completion
2022-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject CORT125329 Unknown 30 mg Oral
Background Prednisone Other / unclassified 25 mg Oral

Indications

No indication recorded.